The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2
about
Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytesEngagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cellsIdentification and characterization of leukocyte-associated Ig-like receptor-1 as a major anchor protein of tyrosine phosphatase SHP-1 in hematopoietic cellsIdentification, characterization and leucocyte expression of Siglec-10, a novel human sialic acid-binding receptorDefining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophilsSiglecs in the immune systemGenetics ignite focus on microglial inflammation in Alzheimer's diseaseSiglecs and immune regulationA study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicingmSiglec-E, a novel mouse CD33-related siglec (sialic acid-binding immunoglobulin-like lectin) that recruits Src homology 2 (SH2)-domain-containing protein tyrosine phosphatases SHP-1 and SHP-2Cloning and characterization of Siglec-10, a novel sialic acid binding member of the Ig superfamily, from human dendritic cells.Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes.A comparative study of the asparagine-linked oligosaccharides on siglec-5, siglec-7 and siglec-8, expressed in a CHO cell line, and their contribution to ligand recognition.Sequence specificity of SHP-1 and SHP-2 Src homology 2 domains. Critical roles of residues beyond the pY+3 position.Evidence for C1q-mediated crosslinking of CD33/LAIR-1 inhibitory immunoreceptors and biological control of CD33/LAIR-1 expression.Identification and characterization of S2V, a novel putative siglec that contains two V set Ig-like domains and recruits protein-tyrosine phosphatases SHPs.New functions for the sialic acid-binding adhesion molecule CD22, a member of the growing family of Siglecs.Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation.Pemphigus vulgaris autoantibody profiling by proteomic technique.CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in miceSurface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cellsDistinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity.CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.Steering Siglec-Sialic Acid Interactions on Living Cells using Bioorthogonal Chemistry.Siglec1 suppresses antiviral innate immune response by inducing TBK1 degradation via the ubiquitin ligase TRIM27.Recent advances in targeted therapy of human myelogenous leukaemia.Is targeted therapy feasible in acute myelogenous leukemia?Host and pathogen hyaluronan signal through human siglec-9 to suppress neutrophil activation.Tonic B-cell and viral ITAM signaling: context is everything.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinEnhanced T cell function in a mouse model of human glycosylation.Basic and clinical immunology of SiglecsAnti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.Mechanism and function of monoclonal antibodies targeting siglec-15 for therapeutic inhibition of osteoclastic bone resorption.Development of Sialic Acid-coated Nanoparticles for Targeting Cancer and Efficient Evasion of the Immune System.Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy.What happened to anti-CD33 therapy for acute myeloid leukemia?CD33-related siglecs as potential modulators of inflammatory responses.Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.Associations of genetic polymorphisms of Siglecs with human diseases.
P2860
Q22010812-25F95D83-84D4-4CB1-9A76-0BCDAFF83B30Q22010987-4B515986-01DA-412E-8F2E-24D82842BFDAQ22253887-943A54EA-9FF9-4FBA-8F42-1DBFD9D4942DQ24532754-3FFB1A82-F777-4A42-86EF-1D30E36F8D2EQ24678441-24BCF428-4F88-4AA9-8EDB-B309F4A038E3Q24682458-DF663E75-2E0E-4EAA-AE45-A00199BF910BQ26781865-36D3C4CA-AE31-43A4-B7EE-F205ACB8E6CCQ26992091-2589903A-028A-4B88-B9F9-A040E7AEC091Q28288986-DB3F6075-FE86-4158-8521-549A8F8072AEQ28347604-CE329CE5-31EA-44D1-A8F5-2A2A7104540EQ30669536-56A1700D-8D56-4A64-A4F0-CDC27C5EB466Q30868758-658744DC-5645-466A-8D0C-D0F92F6A0669Q32081092-02971120-5CDC-44A6-81BD-343A76935BDEQ33243531-8DF098DF-9FE4-468F-B177-D04A95E8ABC9Q33625486-B1DDD13C-FCA7-4BBB-897C-CED7348D9A98Q33944757-E31E10C6-EBD7-4262-9B47-B4071B140B16Q34184901-CDE548FB-D6CF-4E24-B6ED-A3C883FEB4AEQ34403249-86342F03-F039-48D0-AC37-FEFB6A4C68C3Q34625548-DFA9CDC6-4BA5-4B78-9B24-144808AE0D2DQ35019914-BA28AFB7-41CA-4842-9EC4-FBDDADCC3EB1Q35895107-427C3848-17F9-4E2D-8B2E-84DE15F66597Q35950210-55E6B60A-B9F6-419D-8D69-92FB707D64B8Q35980938-7952BE2C-7124-4EF5-B749-8B8EB7B37FA1Q36279536-1B3F4E32-F83C-4893-B9F0-955281EEE5BBQ36293523-034A29F0-2819-4CC8-AC0F-4A1021C94805Q36318531-EBBFC459-18DE-42B9-B24C-155F969FAF17Q36416358-2C15DCA9-137E-4D23-966D-4C8A1E6066CBQ36614661-25685DF5-2390-4952-B4F4-779B2A51B273Q36877363-2D78B7C8-2822-4467-847A-B644F3BA6893Q36932014-8FCE4AB8-B5B8-495F-B961-734B57D13494Q36951529-9B2C560C-30C7-41B9-A2B4-EE9C0617E028Q37348437-D84EBE91-EAF7-46CB-BAF5-6AC20A24F814Q37381414-BE7254E6-4263-422B-9692-438F9C500950Q37622547-FE1C048B-6EE5-4EAC-B0E6-A833EA53BE9BQ37738234-E3E02615-E3E9-4DAD-A40F-BAA883F79807Q37818248-31372FEF-5428-4CC4-9C44-F229A1E9DA8AQ37959880-7C5409C1-192E-475A-98EA-B52CDCA262F8Q37986851-C732039B-CB86-42F3-B2A6-749EA6086865Q38109541-026EC748-3028-450A-BCAD-1408334A4B4DQ38212860-151E0FE5-6C7A-481A-9255-451552D670AD
P2860
The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The myeloid-specific sialic ac ...... phosphatases, SHP-1 and SHP-2
@ast
The myeloid-specific sialic ac ...... phosphatases, SHP-1 and SHP-2
@en
The myeloid-specific sialic ac ...... phosphatases, SHP-1 and SHP-2
@en-gb
The myeloid-specific sialic ac ...... phosphatases, SHP-1 and SHP-2
@nl
type
label
The myeloid-specific sialic ac ...... phosphatases, SHP-1 and SHP-2
@ast
The myeloid-specific sialic ac ...... phosphatases, SHP-1 and SHP-2
@en
The myeloid-specific sialic ac ...... phosphatases, SHP-1 and SHP-2
@en-gb
The myeloid-specific sialic ac ...... phosphatases, SHP-1 and SHP-2
@nl
prefLabel
The myeloid-specific sialic ac ...... phosphatases, SHP-1 and SHP-2
@ast
The myeloid-specific sialic ac ...... phosphatases, SHP-1 and SHP-2
@en
The myeloid-specific sialic ac ...... phosphatases, SHP-1 and SHP-2
@en-gb
The myeloid-specific sialic ac ...... phosphatases, SHP-1 and SHP-2
@nl
P2093
P2860
P921
P356
P1476
The myeloid-specific sialic ac ...... phosphatases, SHP-1 and SHP-2
@en
P2093
C D Buckley
D L Simmons
V C Taylor
P2860
P304
11505-11512
P356
10.1074/JBC.274.17.11505
P407
P577
1999-04-01T00:00:00Z